Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Mizuho Securities Remains Neutral on Myriad Genetics (MYGN); Awaiting Reimbursement Progress
February 3, 2016 8:07 AM ESTMizuho Securities reiterated a Neutral rating and $42.00 price target on Myriad Genetics (NASDAQ: MYGN) following the company's 2Q earnings report. MYGN beat consensus revenues by $5mm and EPS by $0.04. However, Mizuho remains sidelined until more progress on reimbursement is seen.
Analyst Eric Criscuolo... More
Myriad Genetics (MYGN) Tops Q2 EPS by 4c
February 2, 2016 4:06 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.45, $0.04 better than the analyst estimate of $0.41. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $189.97 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
... More